Veracyte (VCYT) 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	1-May-14
Document and Entity Information	'	'
Entity Registrant Name	'VERACYTE, INC.	'
Entity Central Index Key	'0001384101	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	21,172,326
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$64,237,000	$71,220,000
Accounts receivable, net of allowance of $135 and $107 as of March 31, 2014 and December 31, 2013	1,191,000	1,143,000
Supplies inventory	2,721,000	2,567,000
Prepaid expenses and other current assets	1,014,000	1,477,000
Total current assets	69,163,000	76,407,000
Property and equipment, net	3,028,000	2,952,000
Restricted cash	118,000	118,000
Other assets	145,000	153,000
Total assets	72,454,000	79,630,000
Current liabilities:	'	'
Accounts payable	7,214,000	5,294,000
Accrued liabilities	5,267,000	7,594,000
Deferred Genzyme co-promotion fee	2,500,000	2,500,000
Current portion of long-term debt	467,000	'
Total current liabilities	15,448,000	15,388,000
Long-term debt, net of current portion	4,467,000	4,899,000
Deferred rent, net of current portion	260,000	286,000
Deferred Genzyme co-promotion fee, net of current portion	1,989,000	2,614,000
Total liabilities	22,164,000	23,187,000
Commitments and contingencies (Note 5)	'	'
Stockholders' equity:	'	'
Common stock, $0.001 par value; 125,000,000 shares authorized, 21,164,410 and 21,143,313 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively	21,000	21,000
Additional paid-in capital	142,592,000	142,071,000
Preferred stock, $0.001 par value; 5,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively	'	'
Accumulated deficit	-92,323,000	-85,649,000
Total stockholders' equity	50,290,000	56,443,000
Total liabilities and stockholders' equity	$72,454,000	$79,630,000

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
CONDENSED BALANCE SHEETS	'	'
Accounts receivable, allowance (in dollars)	$135	$107
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	21,164,410	21,143,313
Common stock, shares outstanding	21,164,410	21,143,313
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS	'	'
Revenue	$7,476	$4,384
Operating expenses:	'	'
Cost of revenue	3,607	2,773
Research and development	2,126	2,010
Selling and marketing	4,336	2,703
General and administrative	3,982	2,791
Total operating expenses	14,051	10,277
Loss from operations	-6,575	-5,893
Interest expense	-111	'
Other income (expense), net	12	-1,002
Net loss and comprehensive loss	($6,674)	($6,895)
Net loss per common share, basic and diluted (in dollars per share)	($0.32)	($9.04)
Shares used to compute net loss per common share, basic and diluted (in shares)	21,148,342	763,021

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net loss	($6,674)	($6,895)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	264	197
Bad debt expense	28	93
Genzyme co-promotion fee amortization	-625	-625
Stock-based compensation	492	204
Change in value of preferred stock liability	'	1,002
Amortization of debt discount and issuance costs	26	'
Interest on debt balloon payment	20	'
Changes in operating assets and liabilities:	'	'
Accounts receivable	-76	12
Supplies inventory	-154	313
Prepaid expenses and current other assets	463	-144
Other assets	-3	14
Accounts payable	2,045	-187
Accrued liabilities and deferred rent	-2,563	-603
Net cash used in operating activities	-6,757	-6,619
Investing activities	'	'
Purchases of property and equipment	-124	-556
Change in restricted cash	'	50
Net cash used in investing activities	-124	-506
Financing activities	'	'
Payment of convertible preferred stock issuance costs	'	-52
Commissions and issuance costs relating to the initial public offering	-129	'
Proceeds from the exercise of common stock options	27	247
Net cash provided by (used in) financing activities	-102	195
Net decrease in cash and cash equivalents	-6,983	-6,930
Cash and cash equivalents at beginning of period	71,220	14,002
Cash and cash equivalents at end of period	$64,237	$7,072

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Organization and Summary of Significant Accounting Policies	'
Organization and Summary of Significant Accounting Policies	'
	1. Organization and Summary of Significant Accounting Policies
	Veracyte, Inc. (the “Company”) was incorporated in the state of Delaware on August 15, 2006 as Calderome, Inc. Calderome operated as an incubator until early 2008. On March 4, 2008, the Company changed its name to Veracyte, Inc. Veracyte is a diagnostics company pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs. The Company specifically targets diseases that often require invasive procedures for an accurate diagnosis - diseases where many healthy patients undergo costly interventions that ultimately prove unnecessary. The Company improves the accuracy of diagnosis at an earlier stage of patient care by deriving clinically actionable genomic information from cytology samples collected in an outpatient setting. The Company’s first commercial solution, the Afirma® Thyroid FNA Analysis, includes as its centerpiece the Gene Expression Classifier (“GEC”). The GEC helps physicians reduce the number of unnecessary surgeries by employing a proprietary 142-gene signature to preoperatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The Company’s operations are based in South San Francisco, California and Austin, Texas, and it operates in one segment in the United States.
	Basis of Presentation
	The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The financial information for the three months ended March 31, 2014 and 2013 is unaudited but includes all adjustments (consisting of only normal recurring adjustments), which the Company considers necessary for a fair presentation of the results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
	The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	Use of Estimates
	The preparation of the unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; contractual allowances; allowance for doubtful accounts; the useful lives of property and equipment; the recoverability of long-lived assets; the determination of fair value of the Company’s common stock prior to the Company’s initial public offering (“IPO”), stock options, preferred stock liability; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.
	Concentrations of Credit Risk and Other Risks and Uncertainties
	The Company’s cash and cash equivalents are deposited with one major financial institution in the United States of America. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.
	Several of the components of the Company’s sample collection kit and test reagents are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company’s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solution, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.
	The Company is also subject to credit risk from its accounts receivable related to its sales of Afirma. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. All of the Company’s accounts receivables are derived from sales of Afirma in the United States.
	Through March 31, 2014, all of the Company’s revenues are derived from the sale of Afirma. The Company’s solution to date has been delivered primarily to physicians in the United States. The Company’s significant third-party payers and their related revenue as a percentage of total revenue are as follows:
		Three Months Ended
		March 31,		March 31,
		2014		2013
	Medicare	29	%	34	%
	United Healthcare	17	%	10	%
	Aetna	10	%	9	%
	Ending balance	56	%	53	%
	Accounts receivable from Medicare amounted to 83% and 78% of accounts receivable as of March 31, 2014 and December 31, 2013. No other third-party payer represented more than 10% of the Company’s accounts receivable balances for these periods.
	Cash and Cash Equivalents
	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market accounts.
	Restricted Cash
	Deposits of $118,000 as of March 31, 2014 and December 31, 2013, respectively, were restricted from withdrawal and held by a bank in the form of collateral for letters of credit. The balance for each respective period consists of a letter of credit totaling $118,000 held as security for the lease of the Company’s office space in South San Francisco, California.
	Allowance for Doubtful Accounts
	The Company estimates an allowance for doubtful accounts against its individual accounts receivable based on estimates of expected reimbursement consistent with historical payment experience in relation to the amounts billed. Bad debt expense is included in general and administrative expense on the Company’s statements of operations and comprehensive loss. Accounts receivable are written off against the allowance when there is other substantive evidence that the account will not be paid. If the financial condition of our customers deteriorates, resulting in an impairment of their ability to make payment, additional allowances may be required.
	The balance of allowance for doubtful accounts as of March 31, 2014 and December 31, 2013, including charges to bad debt expense and write-offs, net of recoveries follows:
		Three Months Ended
		March 31,			December 31,
		2014			2013
		(In thousands)
	Beginning balance	$	107		$	222
	Charged to expense	28			109
	Write-offs, net of recoveries	—			(224		)
	Ending balance	$	135		$	107
	Supplies Inventory
	Supplies inventory consists of test reagents and other consumables used in the sample collection kits and in the GEC and are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis.
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.
	Internal-use Software
	The Company capitalizes costs incurred in the application development stage to design and implement the software used in the tracking and reporting of laboratory activity. Costs incurred in the development of application of the software are capitalized and amortized over an estimated useful life of three years on a straight line basis. The total cost, accumulated depreciation and net book value was $507,000, $227,000 and $280,000 as of March 31, 2014, and was $482,000, $195,000 and $287,000 at December 31, 2013 and are included in property and equipment in the Company’s condensed balance sheets. During the three months ended March 31, 2014 and 2013, the Company capitalized $25,000 and $99,000 of software development costs. Amortization expense totaled $32,000 and $16,000, for the three months ended March 31, 2014 and 2013, respectively.
	Long-lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There were no impairments for the three months ended March 31, 2014 and 2013.
	Bonus Accruals
	The Company accrues for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by the Board of Directors, compensation levels of eligible individuals, and target bonus percentage levels. The Board of Directors and the Compensation Committee of the Board of Directors review and evaluate the performance against these objectives and ultimately determine what discretionary payments are made. As of March 31, 2014 and December 31, 2013, the Company accrued $262,000 and $1.1 million, respectively, for liabilities associated with these employee and executive bonus plans which are included in accrued liabilities in the Company’s condensed balance sheets.
	Fair Value of Financial Instruments
	The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.
	Revenue Recognition
	The Company’s revenue is generated from the provision of diagnostic services using the Afirma solution. The Company’s service is completed upon the delivery of test results to the prescribing physician which triggers the billing for the service. The Company recognizes revenue related to billings for Medicare and commercial carriers on an accrual basis, net of contractual adjustments, when there is a predictable pattern of collectability. These contractual adjustments represent the difference between the list price (the billing rate) and the reimbursement expected to be received from Medicare or commercial payers. Upon ultimate collection, the amount received from Medicare and commercial payers with a predictable pattern of payment is compared to previous estimates and the contractual allowance is adjusted accordingly. Until a contract has been negotiated with a commercial carrier or governmental program, the Afirma solution may or may not be covered by these entities’ existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment directly from the patient, the related revenue is only recognized upon the earlier of payment notification, if applicable, or cash receipt.
	For all services performed, the Company considers whether or not the following revenue recognition criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.
	Persuasive evidence of an arrangement exists and delivery is deemed to have occurred upon delivery of a patient report to the prescribing physician. The assessment of the fixed or determinable nature of the fees charged for diagnostic testing performed and the collectability of those fees require significant judgment by management. Management believes that these two criteria have been met when there is a contracted reimbursement rate and/or a predictable pattern of collectability with individual third-party payers and accordingly, recognizes revenue upon delivery of the patient report. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with their insurance carrier and health plans. Some payers may not cover the Company’s GEC as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of a contracted reimbursement rate or a predictable pattern and history of collectability, the Company believes that the fee is fixed or determinable and collectability is reasonably assured only upon receipt of third-party payer notification of payment or when cash is received and, accordingly, recognizes revenue at that time.
	Cost of Revenue
	Cost of revenue is expensed as incurred and includes material and service costs, including cytopathology testing services performed by a third-party pathology group, stock-based compensation expense, direct labor costs, equipment and infrastructure expenses associated with testing tissue samples, shipping charges to transport samples, and allocated overhead including rent, information technology, equipment depreciation and utilities.
	Research and Development
	Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel-related expenses, stock-based compensation expense, prototype materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies at domestic and international sites, and allocated overhead including rent, information technology, equipment depreciation and utilities.
	Income Taxes
	The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company’s assessment of an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.
	Stock-based Compensation
	Stock-based compensation expense for equity instruments issued to employees is measured based on the grant-date fair value of the awards. The fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing valuation model. The Company recognizes compensation costs on a straight-line basis for all employee stock based compensation awards that are expected to vest over the requisite service period of the awards, which is generally the awards’ vesting period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	Equity instruments issued to non-employees are valued using the Black-Scholes option-pricing valuation model and are subject to remeasurement as the underlying equity instruments vest.
	Net Loss per Common Share
	Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of convertible preferred stock and options to purchase common stock are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.
Recent Accounting Pronouncements
In July 2013, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures and are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company adopted this guidance during the first quarter of 2014 and such adoption did not have a material impact on the Company’s condensed financial statements.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2014
Net Loss Per Common Share	'
Net Loss Per Common Share	'
	2. Net Loss Per Common Share
	The following table presents the calculation of basic and diluted net loss per common share for the three months ended March 31, 2014 and 2013 (in thousands, except share and per share amounts):
		Three Months Ended
		March 31,			March 31,
		2014			2013
	Net loss	$	(6,674	)	$	(6,895	)
	Shares used to compute net loss per common share, basic and diluted	21,148,342			763,021
	Net loss per common share, basic and diluted	$	(0.32	)	$	(9.04	)
	The following outstanding shares of common stock equivalents have been excluded from diluted net loss per common share for the three months ended March 31, 2014 and 2013 because their inclusion would be anti-dilutive:
		Three Months Ended
		March 31,		March 31,
		2014		2013
	Shares of common stock subject to outstanding options	3,166,419		2,313,107
	Shares of common stock issuable upon conversion of preferred stock	—		13,271,122
	Total shares of common stock equivalents	3,166,419		15,584,229

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities	'
Accrued Liabilities	'
	3. Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Accrued compensation expenses	$	1,095	$	1,962
	Accrued Genzyme co-promotion fees	2,776		4,915
	Accrued other	1,396		717
	Accrued liabilities	$	5,267	$	7,594

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	4. Fair Value Measurements
	The Company records its financial assets and liabilities at fair value. The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. The carrying value of debt approximates its fair value because the interest rate approximates market rates that the Company could obtain for debt with similar terms. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value, and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:
	·                  Level I: Inputs which include quoted prices in active markets for identical assets and liabilities.
	·                  Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	·                  Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table sets forth the fair value of the Company’s financial assets measured on a recurring basis, as of March 31, 2014 and December 31, 2013 (in thousands):
		As of March 31, 2014
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	63,666	$	—	$	—	$	63,666
	Total financial assets	$	63,666	$	—	$	—	$	63,666
		As of December 31, 2013
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	69,972	$	—	$	—	$	69,972
	Total financial assets	$	69,972	$	—	$	—	$	69,972

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies	'
Commitments and Contingencies	'
	5. Commitments and Contingencies
	Operating Leases
	The Company leases its headquarters and South San Francisco laboratory facilities under a non-cancelable lease agreement that expires March 31, 2016. The Company provided security deposits in the form of irrevocable standby letters of credit secured with restricted cash deposits at the Company’s primary bank. The Company deposited $118,000 in restricted cash accounts as collateral for the lease which is included in restricted cash in the Company’s condensed balance sheets as of March 31, 2014 and December 31, 2013.
	The Company leases laboratory space in Austin, Texas. The lease expires on July 31, 2018. The Company provided a cash security deposit of $75,000, which is included in other assets in the Company’s balance sheet as of March 31, 2014 and December 31, 2013.
	Future minimum lease payments under non-cancelable operating leases as of March 31, 2014 are as follows (in thousands):
	Year Ending December 31,	Amount
	April through December 31, 2014	$	712
	2015	989
	2016	413
	2017	222
	2018	130
	Total minimum lease payments	$	2,466
	The Company recognizes rent expense on a straight-line basis over the non-cancelable lease period. Facilities rent expense was $213,000 and $216,000 for the three months ended March 31, 2014 and 2013, respectively.
	Volume Purchase Agreement
	The Company had non-cancelable purchase obligations to contract manufacturers and suppliers for approximately $196,000 at March 31, 2014, all of which is estimated to be payable before December 31, 2014.
	Contingencies
	From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. The Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on the financial position, results of operations or cash flows.

Debt

Debt	3 Months Ended
	Mar. 31, 2014
Debt	'
Debt	'
	6. Debt
	In June 2013, the Company entered into a loan and security agreement with a financial institution to fund its working capital and other general corporate needs. The agreement provided for term loans of up to $10.0 million in aggregate. The Company drew down $5.0 million in funds under the agreement in June 2013, and did not draw the remaining $5.0 million on or before the expiration date of March 31, 2014. The carrying value of the debt approximates its fair value because the interest rate approximates market rates that the Company could obtain for debt with similar terms. The Company’s long-term debt obligation is a Level III liability. Level III inputs include unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the underlying asset or liability.
	The Company is required to repay the outstanding principal in 30 equal installments beginning 18 months after the date of the borrowing and is due in full in June 2017. The loan bears interest at a rate of 6.06% per annum. The loan carries prepayment penalties of 2.25% and 1.5% for prepayment within one and two years, respectively, of the loan origination and 0.75% thereafter. As of March 31, 2014, the net debt obligation is $4.9 million, consisting of the $5.0 million borrowing and the unpaid accrued balloon payment obligation net of the $100,000 discount on the note, of which $467,000 is included in current liabilities and $4.5 million is included in long-term debt in the Company’s balance sheets. The obligation includes an end of term payment of $223,000, representing 4.45% of the total outstanding principal balance, which accretes over the life of the loan as interest expense. As a result of the debt discount and the end of term payment, the effective interest rate for the loan differs from the contractual rate. Total interest on the debt was $111,000 for the three months ended March 31, 2014, comprised of $76,000 of nominal interest and $35,000 in interest expense related to the amortization of the debt discount and accretion of the end of term payment.
	The Company’s obligations under the loan and security agreement are secured by a security interest in substantially all of its assets, excluding its intellectual property and certain other assets. The loan and security agreement contains customary conditions related to borrowing, events of default, and covenants, including covenants limiting the Company’s ability to dispose of assets, undergo a change in control, merge with or acquire other entities, incur debt, incur liens, pay dividends or other distributions to holders of its capital stock, repurchase stock and make investments, in each case subject to certain exceptions. The agreement also allows the lender to call the debt in the event there is a material adverse change in the Company’s business or financial condition. The loan and security agreement does not require that the Company comply with any financial covenants.

Convertible_Preferred_Stock_Wa

Convertible Preferred Stock Warrant	3 Months Ended
	Mar. 31, 2014
Convertible Preferred Stock Warrant	'
Convertible Preferred Stock Warrant	'
	7. Convertible Preferred Stock Warrant
	In June 2013, in conjunction with the execution of the loan and security agreement, as discussed in Note 6, the Company issued to the lender a warrant to purchase up to 49,602 shares of Series C convertible preferred stock with an exercise price of $7.56 per share. Upon the draw down of the $5.0 million term loan, the related warrant became exercisable for 24,801 shares. The lender exercised the warrant with respect to 24,801 shares through a cashless exercise in March 2014 resulting in the issuance of 13,739 shares of the Company’s common stock.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity	'
Stockholders' Equity	'
	8. Stockholders’ Equity
	Common Stock
	The Company’s Restated Certificate of Incorporation authorizes the Company to issue 125,000,000 shares of common stock with a par value of $0.001 per share. The holder of each share of common stock shall have one vote for each share of stock. The common stockholders are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all series of convertible preferred stock outstanding. No dividends have been declared as of March 31, 2014.
	As of March 31, 2014 and December 31, 2013, the Company had reserved shares of common stock for issuance as follows:
		March 31,	December 31,
		2014	2013
	Options issued and outstanding	3,166,419	2,359,287
	Options available for grant under stock option plans	973,312	1,787,802
	Common stock warrants issued and outstanding	—	24,801
	Total	4,139,731	4,171,890
	Preferred Stock
	The Company’s Restated Certificate of Incorporation authorizes the Company to issue 5,000,000 shares of preferred stock with a par value of $0.001 per share. No shares were issued and outstanding at March 31, 2014 or December 31, 2013.

Stock_Incentive_Plans

Stock Incentive Plans	3 Months Ended
	Mar. 31, 2014
Stock Incentive Plans	'
Stock Incentive Plans	'
	9. Stock Incentive Plans
	The following table summarizes activity under the Company’s stock option plans (intrinsic value in thousands):
		Shares		Stock		Weighted			Weighted	Aggregate
		Available		Options		Average			Average	Intrinsic
		for Grant		Outstanding		Exercise Price			Remaining	Value
									Contractual
									Life
									(Years)
	Balance - December 31, 2013	1,787,802		2,359,287		$	3.07		7.84	$	26,964
	Granted	(850,092	)	850,092		15.05
	Canceled	35,602		(35,602	)	8.06
	Exercised	—		(7,358	)	3.69
	Balance - March 31, 2014	973,312		3,166,419		$	6.23		8.09	$	34,652
	Options exercisable - March 31, 2014			2,104,032		$	2.88		7.33	$	29,984
	Options vested and expected to vest - March 31, 2014			2,994,431		$	6.04		8.03	$	33,330
	The aggregate intrinsic value was calculated as the difference between the exercise price of the options to purchase common stock and the fair market value of the Company’s common stock of $17.13 per share as of March 31, 2014.
	Outstanding and exercisable stock options at March 31, 2014 are summarized as follows:
		Options Outstanding				Options Vested and Exercisable
	Exercise	Number		Weighted-Average		Number		Weighted-Average
	Price			Remaining				Remaining
				Contractual				Contractual
				Life (in Years)				Life (in Years)
	$0.08	177,750		3.81		177,750		3.81
	$0.80	165,569		5.49		165,569		5.49
	$2.36	412,009		6.43		393,803		6.43
	$2.40	208,593		7.44		174,226		7.45
	$2.68	650,045		7.92		601,163		7.91
	$4.00	455,861		8.73		404,716		8.72
	$6.04	197,875		9.22		153,055		9.22
	$7.92	9,000		9.45		—		—
	$12.12	39,625		9.51		33,750		9.51
	$14.34-18.24	850,092		9.9		—		—
	$0.08-18.24	3,166,419		8.09		2,104,032		7.33
	The weighted average fair value of stock options granted was $10.27 and $2.71 per share for the three months ended March 31, 2014 and 2013, respectively.
	The weighted average fair value of stock options vested was $2.37 and $2.07 per share for the three months ended March 31, 2014 and 2013, respectively. The aggregate estimated grant date fair value of employee options to purchase common stock vested during the three months ended March 31, 2014 and 2013 was $0.4 million and $0.6 million, respectively
	The weighted average fair value of stock options exercised was $2.53 and $0.87 per share for the three months ended March 31, 2014 and 2013, respectively. The intrinsic value of stock options exercised was $0.1 million and $0.5 million for the three months ended March 31, 2014 and 2013, respectively.
	Stock-based Compensation
	The following table summarizes stock-based compensation expense related to stock options for the three months ended March 31, 2014 and 2013, and are included in the unaudited statements of operations and comprehensive loss as follows (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Cost of revenue	9		4
	Research and development	107		45
	Selling and marketing	93		35
	General and administrative	283		120
	Total	492		204
	As of March 31, 2014, the Company had $9.2 million of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over an estimated weighted-average period of 3.6 years.
	The estimated grant date fair value of employee stock options was calculated using the Black-Scholes option-pricing valuation model, based on the following assumptions:
		Three Months Ended
		March 31,
		2014		2013
	Weighted-average volatility	77.17-78.54%		80.52-81.41%
	Weighted-average expected term (years)	6.08		5.0-6.08
	Risk-free interest rate	1.83-1.99%		0.88-1.16%
	Expected dividend yield	0%		0%
	Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned. The fair value of the stock options granted is calculated at each reporting date using the Black-Scholes option-pricing model with the following assumptions: expected life is equal to the remaining contractual term of the award as of the measurement date ranging from 8.68 years to 9.51 years as of March 31, 2014 and 8.47 years to 9.68 years as of March 31, 2013; risk free rate is based on the U.S. Treasury Constant Maturity rate with a term similar to the expected life of the option at the measurement date ranging from 2.54% to 2.66% as of March 31, 2014 and 1.55% to 1.80% as of March 31, 2013; expected dividend yield of 0%; and volatilities ranging from 76.70% to 76.87% as of March 31, 2014 and 80.27% to 80.99% as of March 31, 2013.

Genzyme_Copromotion_Agreement

Genzyme Co-promotion Agreement	3 Months Ended
	Mar. 31, 2014
Genzyme Co-promotion Agreement	'
Genzyme Co-promotion Agreement	'
	10. Genzyme Co-promotion Agreement
	In May 2011, the Company received $100,000 from Genzyme Corporation (“Genzyme”) in connection with an extension of an exclusive right to negotiate a co-promotion agreement.  In January 2012, the Company and Genzyme executed a co-promotion agreement for the co-exclusive rights and license to promote and market the Company’s Afirma thyroid cancer solution in the United States and in 40 named countries. In exchange, the Company received a $10.0 million co-promotion fee from Genzyme in February 2012. The Company may receive an additional $3.0 million in payments, $600,000 for each country outside of the United States in which the Company obtains marketing authorization and achieves a specified level of reimbursement, for up to five countries. Under the terms of the agreement, Genzyme will receive a percentage of cash receipts that the Company has received related to Afirma as co-promotion fees. The percentage was 50% in 2012, 40% from January 2013 through February 2014, and 32% beginning in March 2014 and thereafter. Genzyme will also spend up to $500,000 for qualifying clinical development activities in countries that require additional testing for approval. This obligation expires in July 2014. The agreement expires in January 2027 and either party may terminate the agreement at any time and with six months prior notice. The Company is amortizing the co-promotion fee over a four-year period, which is management’s best estimate of the life of the agreement, in part because after that period either party may terminate the agreement without penalty. The Company incurred $2.8 million and $1.9 million in co-promotion expense in the three months ended March 31, 2014 and 2013, respectively, which is included in selling and marketing expenses the statements of operations and comprehensive loss. The Company amortized $625,000 of the $10.0 million up-front co-promotion fee in each of the three months ended March 31, 2014 and 2013, which is reflected as a reduction to selling and marketing expenses in the statements of operations and comprehensive loss.  The Company’s outstanding obligation to Genzyme totaled $7.7 million and $6.7 million at March 31, 2014 and December 31, 2013, respectively.  Of the $7.7 million obligation at March 31, 2014, $4.9 million is included in accounts payable and $2.8 million is included in accrued liabilities in the Company’s condensed balance sheets.  Of the $6.7 million obligation at December 31, 2013, $1.8 million is included in accounts payable and $4.9 million is included in accrued liabilities in the Company’s condensed balance sheets.
	The unamortized balance of the co-promotion fee is reflected on the Company’s condensed balance sheets as follows (in thousands):
		March 31,		December 31,
		2014		2013
	Current liabilities:
	Deferred Genzyme co-promotion fee	$	2,500	$	2,500
	Long-term liabilities:
	Deferred Genzyme co-promotion fee, net of current portion	1,989		2,614
	Total	$	4,489	$	5,114

Thyroid_Cytology_Partners

Thyroid Cytology Partners	3 Months Ended
	Mar. 31, 2014
Thyroid Cytology Partners	'
Thyroid Cytology Partners	'
	11. Thyroid Cytology Partners
	In 2010, the Company entered into an arrangement with Pathology Resource Consultants, P.A. (“PRC”) to set up and manage a specialized pathology practice to provide testing services to the Company. There is no direct monetary compensation from the Company to PRC as a result of this arrangement. The Company’s service agreement is with the specialized pathology practice, Thyroid Cytopathology Partners (“TCP”), and is effective through December 31, 2015, unless terminated earlier, and renews annually thereafter. Under the service agreement, Veracyte pays TCP based on a fixed price per test schedule, which is reviewed periodically for changes in market pricing. Subsequent to December 2012, an amendment to the service agreement allows TCP to use a portion of Veracyte’s facility in Austin, Texas. The Company does not have an ownership interest in or provide any form of financial or other support to TCP. The Company has concluded that TCP represents a variable interest entity and that the Company is not the primary beneficiary as it does not have the ability to direct the activities that most significantly impact TCP’s economic performance. Therefore, the Company does not consolidate TCP. All amounts paid to TCP under the service agreement are expensed as incurred and included in cost of revenue in the statements of operations and comprehensive loss. All amounts to be received from TCP will be recorded in the same period as the corresponding lease costs. The Company incurred $887,000 and $711,000 in cytopathology testing and evaluation services expenses with TCP in the three months ended March 31, 2014 and 2013, respectively. The Company’s outstanding obligations to TCP for cytopathology testing services were $584,000 and $588,000 as of March 31, 2014 and December 31, 2013, respectively, and are included in accounts payable in the Company’s condensed balance sheets.
	Beginning in May 2013, TCP reimburses the Company for a proportionate share of the Company’s rent and related operating expense costs for the leased facility. TCP’s portion of rent and related operating expense costs for the shared space at the Austin, Texas facility was $20,000 for the three months ended March 31, 2014, and is included in other income in the Company’s statements of operations and comprehensive loss. The Company’s receivable from TCP for rent expense was $1,000 as of March 31, 2014 which is included in prepaid expenses and other current assets in the Company’s balance sheet.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Taxes	'
Income Taxes	'
	12. Income Taxes
	The Company did not record a provision or benefit for income taxes during the three months ended March 31, 2014 and 2013, respectively.  The Company continues to maintain a valuation allowance for its U.S. federal and state deferred tax assets.
	On January 2, 2013, The American Taxpayer Relief Act of 2012 (“ATRA”), was signed into law. Under prior law, a taxpayer was entitled to a research tax credit for qualifying amounts incurred through December 31, 2011. The ATRA extends the research credit for two years for qualified research expenditures incurred through the end of 2013. The extension of the research credit is retroactive and includes amounts incurred after 2011.
	At March 31, 2014, the Company had $0.8 million of unrecognized tax benefit, none of which, if recognized, would affect the effective tax rate as most of the unrecognized tax benefit is deferred tax assets currently offset by a valuation allowance.
	The Company has not recognized any interest and penalties related to uncertain tax positions as part of the income tax provision.
	The Company files annual income tax returns in the United States only.  A number of years may elapse before an uncertain tax position is audited and finally resolved.  While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its reserves for income taxes reflect the most likely outcome.  The Company adjusts these reserves, as well as the related interest, in light of changing facts and circumstances.  Settlement of any particular position could require the use of cash.  As of March 31, 2014, changes to the Company’s uncertain tax positions in the next twelve months that are reasonably possible are not expected to have a significant impact on the Company’s financial position or results of operations.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Organization and Summary of Significant Accounting Policies	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The financial information for the three months ended March 31, 2014 and 2013 is unaudited but includes all adjustments (consisting of only normal recurring adjustments), which the Company considers necessary for a fair presentation of the results of operations for those periods. Interim results are not necessarily indicative of results for the full fiscal year.
	The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
Use of Estimates	'
	Use of Estimates
	The preparation of the unaudited interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; contractual allowances; allowance for doubtful accounts; the useful lives of property and equipment; the recoverability of long-lived assets; the determination of fair value of the Company’s common stock prior to the Company’s initial public offering (“IPO”), stock options, preferred stock liability; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.
Concentrations of Credit Risk and Other Risks and Uncertainties	'
	Concentrations of Credit Risk and Other Risks and Uncertainties
	The Company’s cash and cash equivalents are deposited with one major financial institution in the United States of America. Deposits in this institution may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents.
	Several of the components of the Company’s sample collection kit and test reagents are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company’s requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solution, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.
	The Company is also subject to credit risk from its accounts receivable related to its sales of Afirma. The Company generally does not perform evaluations of customers’ financial condition and generally does not require collateral. All of the Company’s accounts receivables are derived from sales of Afirma in the United States.
	Through March 31, 2014, all of the Company’s revenues are derived from the sale of Afirma. The Company’s solution to date has been delivered primarily to physicians in the United States. The Company’s significant third-party payers and their related revenue as a percentage of total revenue are as follows:
		Three Months Ended
		March 31,		March 31,
		2014		2013
	Medicare	29	%	34	%
	United Healthcare	17	%	10	%
	Aetna	10	%	9	%
	Ending balance	56	%	53	%
	Accounts receivable from Medicare amounted to 83% and 78% of accounts receivable as of March 31, 2014 and December 31, 2013. No other third-party payer represented more than 10% of the Company’s accounts receivable balances for these periods.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase. Cash equivalents consist primarily of amounts invested in money market accounts.
Restricted Cash	'
	Restricted Cash
	Deposits of $118,000 as of March 31, 2014 and December 31, 2013, respectively, were restricted from withdrawal and held by a bank in the form of collateral for letters of credit. The balance for each respective period consists of a letter of credit totaling $118,000 held as security for the lease of the Company’s office space in South San Francisco, California.
Allowance for Doubtful Accounts	'
	Allowance for Doubtful Accounts
	The Company estimates an allowance for doubtful accounts against its individual accounts receivable based on estimates of expected reimbursement consistent with historical payment experience in relation to the amounts billed. Bad debt expense is included in general and administrative expense on the Company’s statements of operations and comprehensive loss. Accounts receivable are written off against the allowance when there is other substantive evidence that the account will not be paid. If the financial condition of our customers deteriorates, resulting in an impairment of their ability to make payment, additional allowances may be required.
	The balance of allowance for doubtful accounts as of March 31, 2014 and December 31, 2013, including charges to bad debt expense and write-offs, net of recoveries follows:
		Three Months Ended
		March 31,			December 31,
		2014			2013
		(In thousands)
	Beginning balance	$	107		$	222
	Charged to expense	28			109
	Write-offs, net of recoveries	—			(224		)
	Ending balance	$	135		$	107
Supplies Inventory	'
	Supplies Inventory
	Supplies inventory consists of test reagents and other consumables used in the sample collection kits and in the GEC and are valued at the lower of cost or market value. Cost is determined using actual costs on a first-in, first-out basis.
Property and Equipment	'
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations and comprehensive loss in the period realized.
Internal-use Software	'
	Internal-use Software
	The Company capitalizes costs incurred in the application development stage to design and implement the software used in the tracking and reporting of laboratory activity. Costs incurred in the development of application of the software are capitalized and amortized over an estimated useful life of three years on a straight line basis. The total cost, accumulated depreciation and net book value was $507,000, $227,000 and $280,000 as of March 31, 2014, and was $482,000, $195,000 and $287,000 at December 31, 2013 and are included in property and equipment in the Company’s condensed balance sheets. During the three months ended March 31, 2014 and 2013, the Company capitalized $25,000 and $99,000 of software development costs. Amortization expense totaled $32,000 and $16,000, for the three months ended March 31, 2014 and 2013, respectively.
Long-lived Assets	'
	Long-lived Assets
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There were no impairments for the three months ended March 31, 2014 and 2013.
Bonus Accruals	'
	Bonus Accruals
	The Company accrues for liabilities under discretionary employee and executive bonus plans. These estimated compensation liabilities are based on progress against corporate objectives approved by the Board of Directors, compensation levels of eligible individuals, and target bonus percentage levels. The Board of Directors and the Compensation Committee of the Board of Directors review and evaluate the performance against these objectives and ultimately determine what discretionary payments are made. As of March 31, 2014 and December 31, 2013, the Company accrued $262,000 and $1.1 million, respectively, for liabilities associated with these employee and executive bonus plans which are included in accrued liabilities in the Company’s condensed balance sheets.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.
Revenue Recognition	'
	Revenue Recognition
	The Company’s revenue is generated from the provision of diagnostic services using the Afirma solution. The Company’s service is completed upon the delivery of test results to the prescribing physician which triggers the billing for the service. The Company recognizes revenue related to billings for Medicare and commercial carriers on an accrual basis, net of contractual adjustments, when there is a predictable pattern of collectability. These contractual adjustments represent the difference between the list price (the billing rate) and the reimbursement expected to be received from Medicare or commercial payers. Upon ultimate collection, the amount received from Medicare and commercial payers with a predictable pattern of payment is compared to previous estimates and the contractual allowance is adjusted accordingly. Until a contract has been negotiated with a commercial carrier or governmental program, the Afirma solution may or may not be covered by these entities’ existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment directly from the patient, the related revenue is only recognized upon the earlier of payment notification, if applicable, or cash receipt.
	For all services performed, the Company considers whether or not the following revenue recognition criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.
	Persuasive evidence of an arrangement exists and delivery is deemed to have occurred upon delivery of a patient report to the prescribing physician. The assessment of the fixed or determinable nature of the fees charged for diagnostic testing performed and the collectability of those fees require significant judgment by management. Management believes that these two criteria have been met when there is a contracted reimbursement rate and/or a predictable pattern of collectability with individual third-party payers and accordingly, recognizes revenue upon delivery of the patient report. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with their insurance carrier and health plans. Some payers may not cover the Company’s GEC as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of a contracted reimbursement rate or a predictable pattern and history of collectability, the Company believes that the fee is fixed or determinable and collectability is reasonably assured only upon receipt of third-party payer notification of payment or when cash is received and, accordingly, recognizes revenue at that time.
Cost of Revenue	'
	Cost of Revenue
	Cost of revenue is expensed as incurred and includes material and service costs, including cytopathology testing services performed by a third-party pathology group, stock-based compensation expense, direct labor costs, equipment and infrastructure expenses associated with testing tissue samples, shipping charges to transport samples, and allocated overhead including rent, information technology, equipment depreciation and utilities.
Research and Development	'
	Research and Development
	Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel-related expenses, stock-based compensation expense, prototype materials, laboratory supplies, consulting costs, costs associated with setting up and conducting clinical studies at domestic and international sites, and allocated overhead including rent, information technology, equipment depreciation and utilities.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company’s assessment of an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit may change as new information becomes available.
Stock-based Compensation	'
	Stock-based Compensation
	Stock-based compensation expense for equity instruments issued to employees is measured based on the grant-date fair value of the awards. The fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing valuation model. The Company recognizes compensation costs on a straight-line basis for all employee stock based compensation awards that are expected to vest over the requisite service period of the awards, which is generally the awards’ vesting period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	Equity instruments issued to non-employees are valued using the Black-Scholes option-pricing valuation model and are subject to remeasurement as the underlying equity instruments vest.
Net Loss per Common Share	'
	Net Loss per Common Share
	Basic net loss per common share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. Potentially dilutive securities consisting of convertible preferred stock and options to purchase common stock are considered to be common stock equivalents and were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2013-11, Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures and are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company adopted this guidance during the first quarter of 2014 and such adoption did not have a material impact on the Company’s condensed financial statements.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Organization and Summary of Significant Accounting Policies	'
Schedule of the Company's significant third-party payers and their related revenue as a percentage of total revenue	'
		Three Months Ended
		March 31,		March 31,
		2014		2013
	Medicare	29	%	34	%
	United Healthcare	17	%	10	%
	Aetna	10	%	9	%
	Ending balance	56	%	53	%
Schedule of balance of allowance for doubtful accounts, including charges to bad debt expense and write-offs, net of recoveries	'
		Three Months Ended
		March 31,			December 31,
		2014			2013
		(In thousands)
	Beginning balance	$	107		$	222
	Charged to expense	28			109
	Write-offs, net of recoveries	—			(224		)
	Ending balance	$	135		$	107

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2014
Net Loss Per Common Share	'
Schedule of the calculation of basic and diluted net loss per common share	'
	The following table presents the calculation of basic and diluted net loss per common share for the three months ended March 31, 2014 and 2013 (in thousands, except share and per share amounts):
		Three Months Ended
		March 31,			March 31,
		2014			2013
	Net loss	$	(6,674	)	$	(6,895	)
	Shares used to compute net loss per common share, basic and diluted	21,148,342			763,021
	Net loss per common share, basic and diluted	$	(0.32	)	$	(9.04	)
Schedule of outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share	'
		Three Months Ended
		March 31,		March 31,
		2014		2013
	Shares of common stock subject to outstanding options	3,166,419		2,313,107
	Shares of common stock issuable upon conversion of preferred stock	—		13,271,122
	Total shares of common stock equivalents	3,166,419		15,584,229

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities	'
Schedule of accrued liabilities	'
	Accrued liabilities consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Accrued compensation expenses	$	1,095	$	1,962
	Accrued Genzyme co-promotion fees	2,776		4,915
	Accrued other	1,396		717
	Accrued liabilities	$	5,267	$	7,594

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements	'
Schedule of fair value of the Company's financial assets measured on a recurring basis	'
	The following table sets forth the fair value of the Company’s financial assets measured on a recurring basis, as of March 31, 2014 and December 31, 2013 (in thousands):
		As of March 31, 2014
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	63,666	$	—	$	—	$	63,666
	Total financial assets	$	63,666	$	—	$	—	$	63,666
		As of December 31, 2013
		Level I		Level II		Level III		Total
	Financial Assets:
	Money market funds	$	69,972	$	—	$	—	$	69,972
	Total financial assets	$	69,972	$	—	$	—	$	69,972

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies	'
Schedule of future minimum lease payments under non-cancelable operating leases	'
	Future minimum lease payments under non-cancelable operating leases as of March 31, 2014 are as follows (in thousands):
	Year Ending December 31,	Amount
	April through December 31, 2014	$	712
	2015	989
	2016	413
	2017	222
	2018	130
	Total minimum lease payments	$	2,466

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity	'
Schedule of reserved shares of common stock for issuance	'
		March 31,	December 31,
		2014	2013
	Options issued and outstanding	3,166,419	2,359,287
	Options available for grant under stock option plans	973,312	1,787,802
	Common stock warrants issued and outstanding	—	24,801
	Total	4,139,731	4,171,890

Stock_Incentive_Plans_Tables

Stock Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2014
Stock incentive plans	'
Summary of activity under the Company's stock option plans	'
	The following table summarizes activity under the Company’s stock option plans (intrinsic value in thousands):
		Shares		Stock		Weighted			Weighted	Aggregate
		Available		Options		Average			Average	Intrinsic
		for Grant		Outstanding		Exercise Price			Remaining	Value
									Contractual
									Life
									(Years)
	Balance - December 31, 2013	1,787,802		2,359,287		$	3.07		7.84	$	26,964
	Granted	(850,092	)	850,092		15.05
	Canceled	35,602		(35,602	)	8.06
	Exercised	—		(7,358	)	3.69
	Balance - March 31, 2014	973,312		3,166,419		$	6.23		8.09	$	34,652
	Options exercisable - March 31, 2014			2,104,032		$	2.88		7.33	$	29,984
	Options vested and expected to vest - March 31, 2014			2,994,431		$	6.04		8.03	$	33,330
Summary of outstanding and exercisable stock options	'
		Options Outstanding				Options Vested and Exercisable
	Exercise	Number		Weighted-Average		Number		Weighted-Average
	Price			Remaining				Remaining
				Contractual				Contractual
				Life (in Years)				Life (in Years)
	$0.08	177,750		3.81		177,750		3.81
	$0.80	165,569		5.49		165,569		5.49
	$2.36	412,009		6.43		393,803		6.43
	$2.40	208,593		7.44		174,226		7.45
	$2.68	650,045		7.92		601,163		7.91
	$4.00	455,861		8.73		404,716		8.72
	$6.04	197,875		9.22		153,055		9.22
	$7.92	9,000		9.45		—		—
	$12.12	39,625		9.51		33,750		9.51
	$14.34-18.24	850,092		9.9		—		—
	$0.08-18.24	3,166,419		8.09		2,104,032		7.33
Schedule of assumptions used to calculate estimated grant date fair value of employee stock options using the Black-Scholes option-pricing valuation model	'
		Three Months Ended
		March 31,
		2014		2013
	Weighted-average volatility	77.17-78.54%		80.52-81.41%
	Weighted-average expected term (years)	6.08		5.0-6.08
	Risk-free interest rate	1.83-1.99%		0.88-1.16%
	Expected dividend yield	0%		0%
Stock-based Compensation	'
Stock incentive plans	'
Summary of stock based compensation expense related to stock options	'
	The following table summarizes stock-based compensation expense related to stock options for the three months ended March 31, 2014 and 2013, and are included in the unaudited statements of operations and comprehensive loss as follows (in thousands):
		Three Months Ended
		March 31,
		2014		2013
	Cost of revenue	9		4
	Research and development	107		45
	Selling and marketing	93		35
	General and administrative	283		120
	Total	492		204

Genzyme_Copromotion_Agreement_

Genzyme Co-promotion Agreement (Tables)	3 Months Ended
	Mar. 31, 2014
Genzyme Co-promotion Agreement	'
Schedule of unamortized balance of the co-promotion fee reflected in the Company's condensed balance sheets	'
	The unamortized balance of the co-promotion fee is reflected on the Company’s condensed balance sheets as follows (in thousands):
		March 31,		December 31,
		2014		2013
	Current liabilities:
	Deferred Genzyme co-promotion fee	$	2,500	$	2,500
	Long-term liabilities:
	Deferred Genzyme co-promotion fee, net of current portion	1,989		2,614
	Total	$	4,489	$	5,114

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
	segment
	institution
Organization and Summary of Significant Accounting Policies	'	'	'
Number of operating segments	1	'	'
Concentrations of Credit Risk and Other Risks and Uncertainties	'	'	'
Number of major financial institutions with which the company's cash and cash equivalents are deposited	1	'	'
Restricted Cash	'	'	'
Deposits	$118,000	'	$118,000
Letter of credit serving as security for lease	118,000	118,000	118,000
Activity of allowance for doubtful accounts	'	'	'
Beginning balance	107,000	222,000	222,000
Charged to expense	28,000	93,000	109,000
Write-offs, net of recoveries	'	'	-224,000
Ending balance	$135,000	'	$107,000
Revenue | Revenue concentration risk	'	'	'
Concentrations of Credit Risk and Other Risks and Uncertainties	'	'	'
Concentrations of credit risk (as a percent)	56.00%	53.00%	'
Revenue | Revenue concentration risk | Medicare	'	'	'
Concentrations of Credit Risk and Other Risks and Uncertainties	'	'	'
Concentrations of credit risk (as a percent)	29.00%	34.00%	'
Revenue | Revenue concentration risk | United Healthcare	'	'	'
Concentrations of Credit Risk and Other Risks and Uncertainties	'	'	'
Concentrations of credit risk (as a percent)	17.00%	10.00%	'
Revenue | Revenue concentration risk | Aetna	'	'	'
Concentrations of Credit Risk and Other Risks and Uncertainties	'	'	'
Concentrations of credit risk (as a percent)	10.00%	9.00%	'
Accounts receivable | Gross receivables concentration risk | Medicare	'	'	'
Concentrations of Credit Risk and Other Risks and Uncertainties	'	'	'
Concentrations of credit risk (as a percent)	83.00%	'	78.00%

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Property and Equipment and Internal-use Software	'	'	'
Net book value	$3,028,000	'	$2,952,000
Minimum	'	'	'
Property and Equipment and Internal-use Software	'	'	'
Estimated useful life	'3 years	'	'
Maximum	'	'	'
Property and Equipment and Internal-use Software	'	'	'
Estimated useful life	'5 years	'	'
Capitalized software	'	'	'
Property and Equipment and Internal-use Software	'	'	'
Estimated useful life	'3 years	'	'
Total cost	507,000	'	482,000
Accumulated depreciation	227,000	'	195,000
Net book value	280,000	'	287,000
Capitalized costs	25,000	99,000	'
Amortization expense	$32,000	$16,000	'

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Long-lived Assets	'	'	'
Impairments	$0	$0	'
Bonus Accruals	'	'	'
Accrued liabilities associated with employee and executive bonus plans	$262,000	'	$1,100,000

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Calculation of basic and diluted net loss per common share	'	'
Net loss	($6,674)	($6,895)
Shares used to compute net loss per common share, basic and diluted	21,148,342	763,021
Net loss per common share, basic and diluted (in dollars per share)	($0.32)	($9.04)
Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share	'	'
Total shares of common stock equivalents (in shares)	3,166,419	15,584,229
Shares of common stock subject to outstanding options	'	'
Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share	'	'
Total shares of common stock equivalents (in shares)	3,166,419	2,313,107
Shares of common stock issuable upon conversion of preferred stock	'	'
Outstanding shares of common stock equivalents that have been excluded from diluted net loss per common share	'	'
Total shares of common stock equivalents (in shares)	'	13,271,122

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities	'	'
Accrued compensation expenses	$1,095	$1,962
Accrued Genzyme co-promotion fees	2,776	4,915
Accrued other	1,396	717
Accrued liabilities	$5,267	$7,594

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Recurring, USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Level I	'	'
Fair value measurements	'	'
Financial Assets	$63,666	$69,972
Level I | Money market funds	'	'
Fair value measurements	'	'
Financial Assets	63,666	69,972
Total	'	'
Fair value measurements	'	'
Financial Assets	63,666	69,972
Total | Money market funds	'	'
Fair value measurements	'	'
Financial Assets	$63,666	$69,972

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Operating Leases	'	'	'
Restricted cash as collateral for lease	$118,000	$118,000	$118,000
Cash security deposit included in other assets	75,000	'	75,000
Future minimum lease payments under non-cancelable operating leases	'	'	'
April through December 31, 2014	712,000	'	'
2015	989,000	'	'
2016	413,000	'	'
2017	222,000	'	'
2018	130,000	'	'
Total minimum lease payments	2,466,000	'	'
Facilities rent expense	213,000	216,000	'
Volume Purchase Agreement	'	'	'
Non-cancelable purchase obligations to contract manufacturers and suppliers	196,000	'	'
Estimated amount payable in 2014	$196,000	'	'

Debt_Details

Debt (Details) (USD $)	3 Months Ended				3 Months Ended	6 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Jun. 30, 2013	Mar. 31, 2014	Jun. 30, 2013
				Loan and security agreement	Term loan	Term loan
						installment
Debt	'	'	'	'	'	'
Maximum borrowing capacity	'	'	'	$10,000,000	'	'
Amount drawn down	'	'	5,000,000	'	'	5,000,000
Amount not drawn	'	'	'	'	5,000,000	'
Number of installments	'	'	'	'	'	30
Period after which debt is repayable	'	'	'	'	'	'18 months
Interest rate (as a percent)	'	'	'	'	'	6.06%
Prepayment penalties for prepayment within one year of the loan origination (as a percent)	'	'	'	'	'	2.25%
Prepayment penalties for prepayment within two years of the loan origination (as a percent)	'	'	'	'	'	1.50%
Prepayment penalties for prepayment after two years of the loan origination (as a percent)	'	'	'	'	'	0.75%
Net debt obligation	'	'	'	'	4,900,000	'
Borrowing	'	'	'	'	5,000,000	'
Debt discount	'	'	'	'	100,000	'
Net debt obligation included in current liabilities	467,000	'	'	'	467,000	'
Net debt obligation included in long-term debt	4,467,000	4,899,000	'	'	4,500,000	'
Amount of end of term payment	'	'	'	'	'	223,000
End of term payment as a percentage of total outstanding principal balance	'	'	'	'	'	4.45%
Interest on the debt	20,000	'	'	'	111,000	'
Nominal interest on the debt excluding amortization of debt discount and accretion	'	'	'	'	76,000	'
Amortization of debt discount and accretion of end of term payment	'	'	'	'	$35,000	'

Convertible_Preferred_Stock_Wa1

Convertible Preferred Stock Warrant (Details) (USD $)	1 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Jun. 30, 2013
Convertible preferred stock warrant	'	'
Amount drawn down of term loan	'	$5
Convertible Preferred Stock Warrant	'	'
Convertible preferred stock warrant	'	'
Number of shares of preferred stock that can be purchased by each warrant	'	49,602
Issuance of convertible preferred stock, issue price (in dollars per share)	'	$7.56
Number of shares for which warrant became exercisable	'	24,801
Issuance of common stock on exercise of warrant (in shares)	13,739	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
	vote
Stockholders' Equity	'	'
Authorized shares of common stock	125,000,000	125,000,000
Par value of shares of common stock (in dollars per share)	$0.00	$0.00
Number of votes for each share of stock	1	'
Dividends declared	$0	'
Common Stock	'	'
Options issued and outstanding (in shares)	3,166,419	2,359,287
Options available for grant under stock option plans (in shares)	973,312	1,787,802
Shares of common stock reserved for issuance	4,139,731	4,171,890
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Options	'	'
Common Stock	'	'
Options issued and outstanding (in shares)	3,166,419	2,359,287
Options available for grant under stock option plans (in shares)	973,312	1,787,802
Common Stock Warrants	'	'
Common Stock	'	'
Common stock warrants issued and outstanding (in shares)	'	24,801

Stock_Incentive_Plans_Details

Stock Incentive Plans (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Shares Available for Grant	'	'
Balance at the beginning of the period (in shares)	1,787,802	'
Granted (in shares)	-850,092	'
Canceled (in shares)	35,602	'
Balance at the end of the period (in shares)	973,312	1,787,802
Stock Options Outstanding	'	'
Balance at beginning of the period (in shares)	2,359,287	'
Granted (in shares)	850,092	'
Canceled (in shares)	-35,602	'
Exercised (in shares)	-7,358	'
Balance at the end of the period (in shares)	3,166,419	2,359,287
Options exercisable at the end of the period (in shares)	2,104,032	'
Options vested and expected to vest at the end of the period (in shares)	2,994,431	'
Weighted Average Exercise Price	'	'
Balance at beginning of the period (in dollars per share)	$3.07	'
Granted (in dollars per share)	$15.05	'
Canceled (in dollars per share)	$8.06	'
Exercised (in dollars per share)	$3.69	'
Balance at the end of the period (in dollars per share)	$6.23	$3.07
Options exercisable at the end of the period (in dollars per share)	$2.88	'
Options vested and expected to vest at the end of the period (in dollars per share)	$6.04	'
Weighted Average Remaining Contractual Life	'	'
Balance at the beginning of the period	'8 years 1 month 2 days	'7 years 10 months 2 days
Balance at the end of the period	'8 years 1 month 2 days	'7 years 10 months 2 days
Options exercisable at the end of the period	'7 years 3 months 29 days	'
Options vested and expected to vest at the end of the period	'8 years 11 days	'
Aggregate Intrinsic Value	'	'
Balance at the beginning of the period (in dollars)	$26,964	'
Balance at the end of the period (in dollars)	34,652	26,964
Options exercisable at the end of the period (in dollars)	29,984	'
Options vested and expected to vest at the end of the period (in dollars)	$33,330	'
Additional disclosures	'	'
Estimated fair value common stock (in dollars per share)	$17.13	'

Stock_Incentive_Plans_Details_

Stock Incentive Plans (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014
$0.08	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$0.08
Options Outstanding, Number (in shares)	177,750
Options Outstanding, Weighted-Average Remaining Contractual Life	'3 years 9 months 22 days
Options Vested and Exercisable, Number (in shares)	177,750
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'3 years 9 months 22 days
$0.80	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$0.80
Options Outstanding, Number (in shares)	165,569
Options Outstanding, Weighted-Average Remaining Contractual Life	'5 years 5 months 26 days
Options Vested and Exercisable, Number (in shares)	165,569
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'5 years 5 months 26 days
$2.36	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$2.36
Options Outstanding, Number (in shares)	412,009
Options Outstanding, Weighted-Average Remaining Contractual Life	'6 years 5 months 5 days
Options Vested and Exercisable, Number (in shares)	393,803
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'6 years 5 months 5 days
$2.40	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$2.40
Options Outstanding, Number (in shares)	208,593
Options Outstanding, Weighted-Average Remaining Contractual Life	'7 years 5 months 8 days
Options Vested and Exercisable, Number (in shares)	174,226
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'7 years 5 months 12 days
$2.68	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$2.68
Options Outstanding, Number (in shares)	650,045
Options Outstanding, Weighted-Average Remaining Contractual Life	'7 years 11 months 1 day
Options Vested and Exercisable, Number (in shares)	601,163
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'7 years 10 months 28 days
$4.00	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$4
Options Outstanding, Number (in shares)	455,861
Options Outstanding, Weighted-Average Remaining Contractual Life	'8 years 8 months 23 days
Options Vested and Exercisable, Number (in shares)	404,716
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'8 years 8 months 19 days
$6.04	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$6.04
Options Outstanding, Number (in shares)	197,875
Options Outstanding, Weighted-Average Remaining Contractual Life	'9 years 2 months 19 days
Options Vested and Exercisable, Number (in shares)	153,055
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'9 years 2 months 19 days
$7.92	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$7.92
Options Outstanding, Number (in shares)	9,000
Options Outstanding, Weighted-Average Remaining Contractual Life	'9 years 5 months 12 days
$12.12	'
Outstanding and exercisable stock options	'
Exercise price (in dollars per share)	$12.12
Options Outstanding, Number (in shares)	39,625
Options Outstanding, Weighted-Average Remaining Contractual Life	'9 years 6 months 4 days
Options Vested and Exercisable, Number (in shares)	33,750
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'9 years 6 months 4 days
$14.34-18.24	'
Outstanding and exercisable stock options	'
Exercise price, low end of range (in dollars per share)	$14.34
Exercise price, high end of range (in dollars per share)	$18.24
Options Outstanding, Number (in shares)	850,092
Options Outstanding, Weighted-Average Remaining Contractual Life	'9 years 10 months 24 days
$0.08-18.24	'
Outstanding and exercisable stock options	'
Exercise price, low end of range (in dollars per share)	$0.08
Exercise price, high end of range (in dollars per share)	$18.24
Options Outstanding, Number (in shares)	3,166,419
Options Outstanding, Weighted-Average Remaining Contractual Life	'8 years 1 month 2 days
Options Vested and Exercisable, Number (in shares)	2,104,032
Options Vested and Exercisable, Weighted-Average Remaining Contractual Life	'7 years 3 months 29 days

Stock_Incentive_Plans_Details_1

Stock Incentive Plans (Details 3) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Stock Incentive Plans	'	'
Weighted average fair value of stock options granted (in dollars per share)	$10.27	$2.71
Weighted average fair value of stock options vested (in dollars per share)	$2.37	$2.07
Stock incentive plans	'	'
Weighted average fair value of stock options exercised (in dollars per share)	$2.53	$0.87
Intrinsic value of stock options exercised (in dollars)	$0.10	$0.50
Employee stock options	'	'
Stock incentive plans	'	'
Aggregate estimated grant date fair value of options to purchase common stock vested (in dollars)	$0.40	$0.60

Stock_Incentive_Plans_Details_2

Stock Incentive Plans (Details 4) (Stock-based Compensation, USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Stock-based compensation	'	'
Share-based compensation expense (in dollars)	$492,000	$204,000
Unrecognized compensation expense (in dollars)	9,200,000	'
Period over which unrecognized compensation expense expected to be recognized	'3 years 7 months 6 days	'
Cost of revenue	'	'
Stock-based compensation	'	'
Share-based compensation expense (in dollars)	9,000	4,000
Research and development	'	'
Stock-based compensation	'	'
Share-based compensation expense (in dollars)	107,000	45,000
Selling and marketing	'	'
Stock-based compensation	'	'
Share-based compensation expense (in dollars)	93,000	35,000
General and administrative	'	'
Stock-based compensation	'	'
Share-based compensation expense (in dollars)	$283,000	$120,000

Stock_Incentive_Plans_Details_3

Stock Incentive Plans (Details 5)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model	'	'
Contractual term	'7 years 3 months 29 days	'
Stock-based Compensation, employees and directors	'	'
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model	'	'
Weighted-average volatility, low end of range (as a percent)	77.17%	80.52%
Weighted-average volatility, high end of range (as a percent)	78.54%	81.41%
Weighted-average expected term	'6 years 29 days	'
Risk-free interest rate, low end of range (as a percent)	1.83%	0.88%
Risk-free interest rate, high end of range (as a percent)	1.99%	1.16%
Expected dividend yield (as a percent)	0.00%	0.00%
Stock-based Compensation, employees and directors | Minimum	'	'
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model	'	'
Weighted-average expected term	'	'5 years
Stock-based Compensation, employees and directors | Maximum	'	'
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model	'	'
Weighted-average expected term	'	'6 years 29 days
Stock-based Compensation, non-employees	'	'
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model	'	'
Weighted-average volatility, low end of range (as a percent)	76.70%	80.27%
Weighted-average volatility, high end of range (as a percent)	76.87%	80.99%
Risk-free interest rate, low end of range (as a percent)	2.54%	1.55%
Risk-free interest rate, high end of range (as a percent)	2.66%	1.80%
Expected dividend yield (as a percent)	0.00%	0.00%
Stock-based Compensation, non-employees | Minimum	'	'
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model	'	'
Contractual term	'8 years 8 months 5 days	'8 years 5 months 19 days
Stock-based Compensation, non-employees | Maximum	'	'
Assumptions used to calculate estimated fair value of stock options using the Black-Scholes option-pricing valuation model	'	'
Contractual term	'9 years 6 months 4 days	'9 years 8 months 5 days

Genzyme_Copromotion_Agreement_1

Genzyme Co-promotion Agreement (Details) (USD $)

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

14 Months Ended

31-May-11

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Feb. 29, 2012

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Jan. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2012

Feb. 28, 2014

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

Co-promotion agreement

country

Accounts payable

Accounts payable

Accrued liabilities

Accrued liabilities

Maximum

Genzyme

Genzyme

Genzyme

Genzyme

country

Genzyme Co-promotion Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount received from Genzyme in connection with an extension of an exclusive right to negotiate co-promotion agreement

$100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of countries outside United States in which marketing authorization is obtained

'

'

'

'

'

'

'

'

40

'

'

'

'

'

'

'

'

'

Co-promotion fee received from Genzyme

'

10,000,000

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional payments that may be received

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Additional payments that may be received for each country outside of the United States in which the company obtains marketing authorization and achieves a specified level of reimbursement

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

Number of countries outside United States for which additional payments may be received

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

'

'

'

Percentage of cash receipts of co-promotion fees received by co-promoter

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

40.00%

Percentage of cash receipts of co-promotion fees received by co-promoter for remaining periods

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32.00%

'

'

'

Maximum amount to be spent by co-promoter for qualifying clinical development activities in countries that require additional testing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

Prior notice period for termination of agreement

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

Amortization period of co-promotion fee

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

Co-promotion expenses

'

'

'

'

'

2,800,000

1,900,000

'

'

'

'

'

'

'

'

'

'

'

Amortization of up-front co-promotion fee

'

625,000

625,000

'

'

625,000

625,000

'

'

'

'

'

'

'

'

'

'

'

Outstanding obligation to Genzyme

'

'

'

'

'

7,700,000

'

6,700,000

'

4,900,000

1,800,000

2,800,000

4,900,000

'

'

'

'

'

Unamortized balance of the co-promotion fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred Genzyme co-promotion fee

'

2,500,000

'

2,500,000

'

2,500,000

'

2,500,000

'

'

'

'

'

'

'

'

'

'

Deferred Genzyme co-promotion fee, net of current portion

'

1,989,000

'

2,614,000

'

1,989,000

'

2,614,000

'

'

'

'

'

'

'

'

'

'

Total

'

'

'

'

'

$4,489,000

'

$5,114,000

'

'

'

'

'

'

'

'

'

'

Thyroid_Cytology_Partners_Deta

Thyroid Cytology Partners (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Thyroid Cytology Partners	'	'	'
Outstanding obligations	$7,214,000	'	$5,294,000
Prepaid expenses and other current assets	1,014,000	'	1,477,000
Thyroid Cytology Partners	'	'	'
Thyroid Cytology Partners	'	'	'
Expenses for cytopathology testing and evaluation services	887,000	711,000	'
Outstanding obligations	584,000	'	588,000
Reduction to rent expense for TCP's portion of costs for shared space	20,000	'	'
Prepaid expenses and other current assets	$1,000	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Jan. 02, 2013	Mar. 31, 2014
Income Taxes	'	'
Period for which research tax credit extended for qualified research expenditures incurred through the end of 2013	'2 years	'
Unrecognized tax benefit	'	$0.80
Unrecognized tax benefits, which if recognized, would affect the effective tax rate	'	$0